These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21153394)

  • 21. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.
    Stein JP; Cai J; Groshen S; Skinner DG
    J Urol; 2003 Jul; 170(1):35-41. PubMed ID: 12796639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy.
    Sejima T; Morizane S; Yao A; Isoyama T; Saito M; Amisaki T; Koumi T; Takenaka A
    Int J Urol; 2014 Jan; 21(1):52-7. PubMed ID: 23711293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Rochefort P; Chabaud S; Pierga JY; Tredan O; Brain E; Bidard FC; Schiffler C; Polena H; Khalil-Mgharbel A; Vilgrain I; Bachelot T
    Br J Cancer; 2017 Jan; 116(3):356-361. PubMed ID: 28056463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma.
    Shariat SF; Kim JH; Andrews B; Kattan MW; Wheeler TM; Kim IY; Lerner SP; Slawin KM
    Cancer; 2001 Dec; 92(12):2985-92. PubMed ID: 11753975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
    Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
    BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.
    Shariat SF; Pahlavan S; Baseman AG; Brown RM; Green AE; Wheeler TM; Lerner SP
    Urology; 2001 Jan; 57(1):60-5. PubMed ID: 11164145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
    Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
    Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Siliconchiptechnology-based MMP-7 analysis in urine: an option for preoperative identification of lymph node metastasis in bladder cancer].
    Jäger T; Tschirdewahn S; Vom Dorp F; Piechotta G; Rübben H; Szarvas T
    Urologe A; 2013 Jun; 52(6):853-8. PubMed ID: 23358831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel risk stratification model, involving preoperative lymphocyte-monocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy.
    Yoshida T; Kinoshita H; Yoshida K; Yanishi M; Inui H; Komai Y; Sugi M; Inoue T; Murota T; Matsuda T
    Jpn J Clin Oncol; 2015 Dec; 45(12):1162-7. PubMed ID: 26423342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.
    Karl A; Tritschler S; Hofmann S; Stief CG; Schindlbeck C
    Eur J Med Res; 2009 Nov; 14(11):487-90. PubMed ID: 19948444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
    Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
    BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
    Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer.
    Garcia del Muro X; Torregrosa A; Muñoz J; Castellsagué X; Condom E; Vigués F; Arance A; Fabra A; Germà JR
    Eur J Cancer; 2000 Feb; 36(3):357-62. PubMed ID: 10708937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.
    Ha YS; Kim SW; Chun SY; Chung JW; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim WT; Kim WJ; Kim TH
    BMC Urol; 2019 Jan; 19(1):10. PubMed ID: 30678673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cadherin switch assessment in the epithelial-mesenchymal transition of urothelial bladder carcinomas.
    Drocaş AI; Tomescu PI; Mitroi G; Drăgoescu PO; Mărgăritescu C; Stepan AE; Şurlin V; CrăiŢoiu Ş; Drocaş I; Ungureanu AM; Găman AE; Turculeanu A; Simionescu CE
    Rom J Morphol Embryol; 2016; 57(3):1037-1044. PubMed ID: 28002521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
    Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
    Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer.
    Shariat SF; Kim J; Nguyen C; Wheeler TM; Lerner SP; Slawin KM
    Urology; 2003 Feb; 61(2):359-64. PubMed ID: 12597948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.